Skip to content
Menu

HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $350 Price Target

Benzinga Newsdesk 21 hours ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $350 price target.

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $350 price target.

Read at benzinga.com